SoFi Technologies Inc (SOFI) Stock Price Today
Aura AI Summary
Key Stats
- $19.08BMarket Cap
- 40,962,271Volume
- FinancialsSector
- $32.2152W High
- $14.2252W Low
- 61 DaysTypical Hold Time
- $19.36BEnterprise Value
- -Div Yield
- 10% Sell | 90% BuyTrading Activity
Track SoFi Technologies Inc (SOFI) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, SoFi Technologies Inc has traded between a low of $14.22 and a high of $32.21, highlighting its annual price range. Buy and sell SoFi Technologies Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Most Recent News
CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.